GreyBird Ventures, LLC is the world’s first venture firm focused exclusively on solving the most critical diagnostic problems to accelerate the trend toward precision medicine.
Launched by Tom Miller, Michael Devlin, and Scott Gazelle, and supported by a global network of Operating Advisors, we invest early and work closely with entrepreneurs who share our passion and belief that the precise diagnosis of disease is the necessary starting point for successful treatment.
We are guided in all of our activities by a strong ethical filter to seek returns that are as humanitarian as they are financially rewarding.
Lawyer & International Investment Professional
mdevlin@greybirdventures.com
Physician-Scientist & Academic Entrepreneur
sgazelle@greybirdventures.com
VIEW BIO
Mara Aspinall is a healthcare pioneer and leader. She is currently CEO of Health Catalysts, an investment and advisory firm dedicated to the growth of new healthcare companies. Mara is also Executive Chair of GenePeeks, a computational genomics firm, and a Director of Abcam pic, 3Scan, Castle Biosciences and Blue Cross Blue Shield of Arizona. She previously served as CEO of Ventana Medical Systems and President of Genzyme Genetics and Genzyme Pharmaceuticals. Mara is Chair of the Arizona Biosciences Board and co-founder of the School of Biomedical Diagnostics at Arizona State University, the first school dedicated to diagnostics as an independent discipline.
VIEW BIO
Russ Clark is a lawyer by training and has more than twenty-five years of experience in cancer related endeavors. He has broad and deep experience in cancer clinical trials as well as information technology to support cancer care and cancer research. Russ has founded or co-founded a number of successful cancer-related companies working with academic cancer centers, community hospitals, oncology practices, payers and biopharmaceutical companies. He has worked in the cancer genomics field since 1998. His network includes many oncology thought leaders who he has worked with on a variety of projects over the years.
VIEW BIO
Michael Hadjisavas has been a leader in the Life Sciences, Applied Markets and Diagnostics industries for over 20 years, including 10 years focusing on genomics, translational research, bioinformatics and molecular diagnostics. He currently serves as VP of Assay Technologies, Head of Life Sciences Portfolio Strategy and previously as VP Clinical Genomics and Bioinformatics at QIAGEN, Inc. His prior positions include executive and senior leadership roles at: Abcam PLC, Gen-Probe/Hologic, Life Technologies/Thermo, and Sigma-Aldrich. His commercial and operational experience includes portfolio responsibilities for systems, consumables and software for the research, pharmaceutical, and diagnostics segments. He has also held numerous strategic advisory roles for various early stage genomics, bioinformatics and diagnostic companies. He holds B.Sc., Honors and Ph.D. degrees in molecular and cellular biology from the University of Adelaide, Australia with post-doctoral training at Texas A&M University. He has an abounding passion and deep commitment for implementing advanced technologies in healthcare.
VIEW BIO
Trevor Hawkins’ 25+ year career in healthcare has included business, academic innovation and entrepreneurship. He is a visiting Professor at NYU and serves on several boards focusing on new technology and innovative solutions. Dr. Hawkins was previously Director of the Human Genome Project for the DOE, and held senior executive roles at Siemens Healthcare, Philips, GE Healthcare and Amersham. He was also previously Chairman & CEO of ProGenTech, a privately held company based in Shanghai & San Francisco, and a founder of the Beijing Genome Institute, of which he remains an Honorary Professor and Director. Dr. Hawkins invented SPRI – Solid Phase Reversible Immobilization – the magnetic bead nucleic acid isolation method used as the sample prep method for the Human Genome Project. Dr. Hawkins has published over 50 peer-reviewed articles on automation, genomics, human diseases and the human genome project.
VIEW BIO
Stefan Herm is a global healthcare IT industry expert and entrepreneur. Following his role as Managing Director of GSD, a Berlin-based enterprise IT company he successfully sold to Siemens, he had executive leadership roles at both McKesson and Nuance. He currently works with McKinsey as an external advisor for Healthcare IT and has done consulting in large hospital IT tenders and implementations in the Middle East. He also works throughout Central and Eastern Europe with Penta Hospitals International, a large private hospital chain, developing its IT strategy.
VIEW BIO
Alice Jacobs is a physician entrepreneur, advisor and investor. She co-founded IMDx while completing Harvard Medical School. Raising $40M in funding and closing almost another $40M in strategic deals the company had five FDA cleared and eight CE marked products before being sold to Qiagen. Alice has been an advisor to Third Rock Ventures, MIT and GE Healthcare Ventures. She holds multiple patents in personalized medicine and has been honored with numerous awards including a “Top 50 Innovators” by the World Economic Forum.
VIEW BIO
Andrew Litt is CEO of Cornice Health Ventures, LLC., which helps others acquire and collaborate with healthcare service companies. Dr. Litt is also an Operating Partner with The Vistria Group, a private equity firm. Until 2014, he was the Chief Medical Officer for Dell’s Healthcare and Life Sciences division. Prior to that, Dr. Litt was Executive Vice President and Vice Dean at the NYU Langone Medical Center, where he was responsible for managing all activities and strategy across the institution. Dr. Litt helped found and was Board Chair of CareCore National, which provides utilization and quality management program. He also was a board member of Imaging on Call. He is currently a board member of Supplemental Health Care, a nurse staffing company and of Captify Health, a GI patient engagement company. Dr. Litt is a neuroradiologist with expertise in neurovascular imaging.
VIEW BIO
Anup Raina is a serial entrepreneur and experienced healthcare executive. He is the co-founder of Reads for Rads, Inc., which provides expert remote teleradiology interpretation services. He is also a business associate at the Drexel University College of Medicine. Anup was previously COO for Wipro’s Global Healthcare Information Technology business (which was acquired from GE), and he also worked for Siemens Healthcare in Corporate Strategy and Consulting. Anup has extensive business connections in India and is fluent in German, English, Hindi and Kashmiri.
VIEW BIO
Frank Wu is the Founder & CEO of JF Healthcare, a firm focused on the development of artificial intelligence imaging technology to increase both the quality and productivity of Radiology in China - a market in which there is an insufficient number of trained radiologists. Previously, Frank was the CEO of Siemens Healthcare for North East Asia, a $1.7B business with over 5000 employees. Under his leadership, China grew 30% per year for three years in a row to allow Siemens to achieve market leadership there. Frank received his MS in computer science from Northwestern Polytechnic University, and his MBA from the China Europe International Business School.
VIEW BIO
Bonnie Blanchfield is a health services researcher and consultant who serves as Director of Finance and Accounting for GreyBird. Bonnie’s 35+ year career started in public accounting. She then moved to corporate management before obtaining a doctoral degree at the Harvard School of Public Health. In her academic activities, Bonnie combines her understanding of accounting and corporate finance with her research skills to produce policy relevant research and program evaluation looking at health care costs, health care delivery redesign, patient safety and quality. She holds a faculty appointment at Harvard Medical School and adjunct appointment at The Dartmouth Institute. Bonnie has served as acting CFO for several small companies, and currently serves as acting CFO for GreyBird portfolio company Atlas 5D.
VIEW BIO
Sarah serves as GreyBird’s Director of Operations. She received her Bachelor’s degree in Business Administration from Merrimack College in 2009 with a concentration in international business, and has worked in the Department of Radiology at Massachusetts General Hospital in an administrative capacity since 2012. Sarah is currently completing a Healthcare MBA program at Simmons College, School of Management in Boston. As part of her MBA program, Sarah is involved in a part-time internship at the MA State House working with Senator Welch, co-Chair of the Healthcare Financing Committee. Her interests lie at the intersection of health policy and business. She is excited to be a part of GreyBird and to support the movement towards precision medicine and its potential to help improve our health system.
GreyBird Ventures LLC (“GreyBird”) has prepared the contents of this web site (“Site”) solely for informational purposes and to assist prospective investors who view this Site (the “Recipients”) in deciding whether to proceed with a further investigation of investments managed by GreyBird. Under no circumstances shall this Site be deemed or construed to be an offer to sell, or the solicitation of an offer to buy, any securities, and it is not intended to be the basis of any investment decision or any decision to subscribe to a GreyBird investment vehicle (“Investments”). GreyBird does not make any representation or warranty, expressed or implied, as to the accuracy or completeness of information on the Site.
This Site contains certain statements and estimates made by GreyBird with respect to the anticipated future performance of its Investments and portfolio companies. Such statements and estimates reflect various assumptions concerning anticipated results, which assumptions may or may not prove to be correct. No representations or warranties are made as to the accuracy of such statements or estimates. This Site is for information only and intended for persons reasonably believed to have sufficient expertise to understand the risks involved.
Past performance is not necessarily indicative of future results, and there can be no assurance that the Investments will achieve comparable results or that GreyBird will be able to implement its strategy or achieve its investment objectives. This Site does not constitute an offer to sell or the solicitation of an offer to buy in any state or other U.S. or non-U.S. jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such state or jurisdiction. This offering does not constitute an offer of interests in the investment programs managed by GreyBird (the “Interests”) to the public, and no action has been or will be taken to permit a public offering in any jurisdiction where action would be required for that purpose. The Interests may not be offered or sold, directly or indirectly, and contents of this site may not be copied, reproduced, and/or distributed in any jurisdiction, except in accordance with the legal requirements applicable in such jurisdiction. Prospective investors should inform themselves as to the legal requirements and tax consequences within the countries of their citizenship, residence, domicile and place of business with respect to the acquisition, holding or disposal of Interests, and any non-U.S. exchange restrictions that may be relevant thereto.
Moreover, certain information contained in this Site constitutes “forward-looking” statements, which can be identified by the use of forward-looking terminology such as “may”, “will”, “seek”, “should”, “expect”, “anticipate”, “project”, “estimate”, “intend”, “continue”, “target”, or “believe” or the negatives thereof or other variations thereon or comparable terminology. Due to various risks and uncertainties, including those set forth herein, actual events or results, projected market conditions, interest rate movements, or consumer or investing trends, the actual performance of the Investments may differ materially from that which is reflected or contemplated in such forward-looking statements.
THE INTERESTS HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), THE SECURITIES LAWS OF ANY STATE OR ANY OTHER APPLICABLE SECURITIES LAWS IN RELIANCE UPON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH LAWS. SUCH INTERESTS MUST BE ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE OFFERED FOR SALE, PLEDGED, HYPOTHECATED, SOLD, ASSIGNED OR TRANSFERRED AT ANY TIME EXCEPT IN COMPLIANCE WITH (I) THE SECURITIES ACT, ANY APPLICABLE STATE SECURITIES LAWS, AND ANY OTHER APPLICABLE SECURITIES LAWS; AND (II) THE TERMS AND CONDITIONS OF THE RELEVANT OPERATING AGREEMENT GOVERNING THE INVESTMENT. THE INTERESTS MAY NOT BE TRANSFERRED OF RECORD EXCEPT IN COMPLIANCE WITH SUCH LAWS AND SUCH OPERATING AGREEMENT. THEREFORE, PURCHASERS OF SUCH INTERESTS WILL BE REQUIRED TO BEAR THE RISK OF THEIR INVESTMENT FOR AN INDEFINITE PERIOD OF TIME.